GSK-1838705A

GSK-1838705A is a potent, orally bioavailable small molecule inhibitor that targets the Insulin-like Growth Factor 1 Receptor (IGF1R), the Insulin Receptor (IR), and Anaplastic Lymphoma Kinase (ALK). Developed by GSK, it functions as an antineoplastic agent by blocking signaling pathways critical for tumor cell proliferation and survival. In preclinical studies, particularly in Acute Myeloid Leukemia (AML) models, GSK-1838705A has demonstrated standalone cytotoxicity and the ability to act as a mediator of etoposide-induced cell death, suggesting potential for combination therapy. It has also been investigated in the context of small-cell lung cancer and other solid tumors where IGF1R or ALK signaling is dysregulated.

Other names

IGF1R inhibitor GSK-1838705AIGF-1R inhibitor GSK-1838705AIGF 1R inhibitor GSK-1838705AALK/IGF1R inhibitor GSK-1838705A